Advertisement

Topics

IRX Therapeutics Announces Presentation of IRX-2 Phase 1b Biomarker Data in Early Stage Breast Cancer

09:30 EST 10 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-- IRX-2 is well-tolerated with encouraging evidence of activity -- -- Upregulation of PD-L1 and other key biomarkers observed -- IRX Therapeutics, Inc. (IRX) announced the presentation of preliminary results from a...

Other Sources for this Article

Media Inquiries
MacDougall Biomedical Communications
Rob Kloppenburg or Kara Mazey, 781-235-3060
rkloppenburg@macbiocom.com
kmazey@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "IRX Therapeutics Announces Presentation of IRX-2 Phase 1b Biomarker Data in Early Stage Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...